BioGene Therapeutics Welcomes Dr. Deepak Sampath, PhD. to Its Board of Directors
PreveCeutical Medical's subsidiary BioGene Therapeutics has appointed Dr. Deepak Sampath as an independent director effective November 21, 2024. Dr. Sampath brings over 25 years of experience in molecular biology, pharmacology, and drug development. Currently serving as Senior Vice President and Head of Research at Ultragenyx, he has contributed significantly to oncological treatments, including the FDA approval of venetoclax for CLL/SLL. His expertise spans protein biologics, nucleic acids, and gene therapies, with 108 published articles and involvement in 32 patents/applications. At Ultragenyx, he leads research in genetic conditions across neurological, metabolic, bone, and muscular diseases.
La sussidiaria di PreveCeutical Medical, BioGene Therapeutics, ha nominato il Dr. Deepak Sampath come direttore indipendente, con effetto dal 21 novembre 2024. Il Dr. Sampath porta con sé oltre 25 anni di esperienza in biologia molecolare, farmacologia e sviluppo di farmaci. Attualmente, ricopre il ruolo di Vicepresidente Senior e Responsabile della Ricerca presso Ultragenyx, dove ha dato un contributo significativo ai trattamenti oncologici, inclusa l'approvazione da parte della FDA del venetoclax per CLL/SLL. La sua esperienza comprende biologici proteici, acidi nucleici e terapie geniche, con 108 articoli pubblicati e un coinvolgimento in 32 brevetti/applicazioni. Presso Ultragenyx, guida la ricerca su condizioni genetiche che riguardano malattie neurologiche, metaboliche, ossee e muscolari.
La subsidiaria de PreveCeutical Medical, BioGene Therapeutics, ha nombrado al Dr. Deepak Sampath como director independiente, efectivo a partir del 21 de noviembre de 2024. El Dr. Sampath aporta más de 25 años de experiencia en biología molecular, farmacología y desarrollo de fármacos. Actualmente se desempeña como Vicepresidente Senior y Jefe de Investigación en Ultragenyx, donde ha realizado contribuciones significativas a tratamientos oncológicos, incluida la aprobación de la FDA de venetoclax para CLL/SLL. Su experiencia abarca biológicos proteicos, ácidos nucleicos y terapias génicas, con 108 artículos publicados y participación en 32 patentes/aplicaciones. En Ultragenyx, lidera la investigación de condiciones genéticas en enfermedades neurológicas, metabólicas, óseas y musculares.
PreveCeutical Medical의 자회사인 BioGene Therapeutics가 Deepak Sampath 박사를 2024년 11월 21일자로 독립 이사로 임명했습니다. Sampath 박사는 분자 생물학, 약리학 및 약물 개발 분야에서 25년 이상의 경험을 보유하고 있습니다. 현재 Ultragenyx에서 수석 부사장 및 연구 책임자로 재직 중이며, CLL/SLL에 대한 venetoclax의 FDA 승인을 포함하여 종양학 치료에 크게 기여했습니다. 그의 전문 분야는 단백질 생물제제, 핵산 및 유전자 치료를 포함하며, 108개의 논문 발표와 32개의 특허/신청에 참여했습니다. Ultragenyx에서 그는 신경계, 대사성, 뼈 및 근육 질환을 포함한 유전적 질병 연구를 이끌고 있습니다.
La filiale de PreveCeutical Medical, BioGene Therapeutics, a nommé le Dr. Deepak Sampath en tant que directeur indépendant, à compter du 21 novembre 2024. Le Dr. Sampath apporte plus de 25 ans d'expérience en biologie moléculaire, en pharmacologie et en développement de médicaments. Actuellement, il est vice-président senior et responsable de la recherche chez Ultragenyx, où il a contribué de manière significative aux traitements oncologiques, y compris l'approbation par la FDA du venetoclax pour CLL/SLL. Son expertise couvre les biologiques protéiques, les acides nucléiques et les thérapies géniques, avec 108 articles publiés et une implication dans 32 brevets/demandes. Chez Ultragenyx, il dirige la recherche sur des maladies génétiques touchant les domaines neurologiques, métaboliques, osseux et musculaires.
Die Tochtergesellschaft von PreveCeutical Medical, BioGene Therapeutics, hat Dr. Deepak Sampath zum unabhängigen Direktor ernannt, wirksam ab dem 21. November 2024. Dr. Sampath bringt über 25 Jahre Erfahrung in molekularer Biologie, Pharmakologie und Arzneimittelentwicklung mit. Derzeit ist er Senior Vice President und Leiter der Forschung bei Ultragenyx und hat erheblich zu onkologischen Behandlungen beigetragen, einschließlich der FDA-Zulassung von Venetoclax für CLL/SLL. Seine Expertise umfasst proteinbasierte Biologika, Nukleinsäuren und Gentherapien mit 108 veröffentlichten Artikeln und der Beteiligung an 32 Patenten/Anträgen. Bei Ultragenyx leitet er die Forschung zu genetischen Erkrankungen im Bereich neurologischer, metabolischer, skelettaler und muskulärer Erkrankungen.
- Appointment of highly experienced director with 25+ years in drug development
- Strong track record in FDA drug approvals (venetoclax)
- Extensive intellectual property portfolio (21 patents, 11 applications)
- Significant research publication history (108 peer-reviewed articles)
- Current leadership position at Ultragenyx in relevant therapeutic areas
- None.
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Deepak Sampath as an independent director effective on 21 November, 2024.
Stephen Van Deventer, CEO of BioGene, commented:
"We are thrilled to welcome Dr. Deepak Sampath to our Board of Directors. Deepak's extraordinary career, spanning over 25 years in molecular and cellular biology, pharmacology, and drug development, adds invaluable expertise to BioGene's leadership team. His track record of advancing programs from discovery to clinical development and regulatory approval aligns seamlessly with our mission to deliver transformative therapies for metabolic and genetic disorders. We look forward to his insights as we continue to expand our impact in the life sciences sector."
Dr. Deepak Sampath's Career Highlights:
Dr. Sampath is a distinguished scientist and seasoned executive leader with extensive experience in small molecules, protein biologics, nucleic acids, and gene therapies. His leadership has driven numerous programs from early research and drug discovery into clinical trials and through regulatory approval for commercialization. Most notably, he has made significant contributions to the treatment of oncological diseases, including the FDA approval of venetoclax, a first-in-class BCL-2 selective inhibitor for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). His additional expertise spans the discovery and development of predictive biomarkers, translational research, target identification and validation. Dr. Sampath has also been instrumental in establishing strategic partnerships with academic institutions and industry leaders, ensuring the successful translation of cutting-edge science into therapeutic breakthroughs. Additionally, he has published 108 articles in peer-reviewed journals and is named as an inventor or co-inventor on 21 issued patents and 11 patent applications.
Currently serving as Senior Vice President and Head of Research at Ultragenyx, Dr. Sampath leads multidisciplinary functions with expertise in the fields of Molecular Genetics, Molecular and Cellular Biology, Molecular Therapeutics, Protein Sciences, Bioinformatics and Bioanalytical Research. Additionally, his focus is on translational research of multiple modalities, such as protein biologics, nucleic acids and gene therapies, for the treatment of Rare and UltraRare Genetic conditons spanning neurological, metabolic, bone and muscular diseases.
Dr. Sampath remarked on his appointment:
"I am honored to join BioGene's Board of Directors and collaborate with this exceptionally talented team. BioGene's commitment to innovation and its strategic focus on addressing critical unmet medical needs resonates deeply with my own professional aspirations and journey. I look forward to contributing to the Company's mission and supporting its endeavors to transform patient care through scientific excellence."
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
About BioGene Therapeutics Inc.
BioGene Therapeutics Inc. ("BioGene") is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly-owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's
On Behalf of the Board of Directors,
PreveCeutical Medical Inc. & BioGene Therapeutics Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer
For further information, please contact:
Stephen Van Deventer
(604) 306-9669
info@PreveCeutical.com
Forward-Looking Statements:
This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding receipt of regulatory and other consents and approvals for the Acquisition; PreveCeutical, PreveCeutical Australia, and BioGene completing the Acquisition as contemplated by the Agreement; PreveCeutical receiving the necessary regulatory and other consents and approvals for the Distribution; and PreveCeutical completing the Distribution as contemplated above. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including adverse market conditions and other factors beyond the control of the parties. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company; regulations and policies affecting the biotechnology or pharmaceutical industry adversely affecting the future results or performance of PreveCeutical or BioGene; the Company's failure to obtain the required consents and approvals for the Acquisition and the Distribution; and the Company determining that the Distribution is not an optimal strategy following tax and business consultations. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231211
FAQ
When did Dr. Deepak Sampath join BioGene Therapeutics' Board of Directors (PRVCF)?
What is Dr. Sampath's current role outside of BioGene Therapeutics (PRVCF)?
How many patents and publications has Dr. Sampath contributed to while working with PRVCF?
What major drug development achievement is highlighted in Dr. Sampath's career with PRVCF?
